Hi Ice....
"Believe DFM invested, in its 14 years, US150 mill plus into its R&D for its TAVR"
I had a look on the internet for DFM and there was mention of 250 employees ...
They MUST have come up with a functional / significant TAVR design .... so the question of relevance to us here is ...
Why didn't anyone buy the IP? ... it was a sitting duck for a cheap buyout by any big pharma .. already in that space (they all would've known about the situation) OR wanting a quick way in
Certainly the Adapt process and the "no stitches" design with single piece weren't known about a couple of years ago ... but still the question stands ... remember this was over 2 years ago .... and given the circumstances in the business space nowdays why if big pharma didn't buy in back then, why would they buy in now? (via Admedus)
Any ideas ?
Any way we can find out for certain?
.
TAVR; the potential of Admedus being part of., page-21
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 760 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 388 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |